
WilmerHale Advises Repare Therapeutics on Worldwide License and Collaboration Agreement with Roche

JUNE 29, 2022

On June 1, 2022, Repare Therapeutics, a leading clinical-stage precision oncology company, [announced](#) it has entered into a worldwide license and collaboration agreement with Roche.

The agreement is for the development and commercialization of camonsertib (also known as RP-3500), a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase) for the treatment of tumors with specific synthetic-lethal genomic alterations including those in the ATM gene (Ataxia-Telangiectasia mutated kinase).

Under the terms of the agreement, Repare will receive a \$125 million upfront payment, and is eligible to receive up to \$1.2 billion in potential clinical, regulatory, commercial and sales milestones, including up to \$55 million in potential near-term payments, and royalties on global net sales ranging from high-single-digits to high-teens.

The WilmerHale team advising Repare Therapeutics was led by [Steven Barrett](#) and [Mat Trachok](#).